These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

175 related items for PubMed ID: 22206598

  • 1. The management impact of clinically significant incidental lesions detected on staging FDG PET-CT in patients with non-small cell lung cancer (NSCLC): an analysis of 649 cases.
    Lin M, Ambati C.
    Lung Cancer; 2012 Jun; 76(3):344-9. PubMed ID: 22206598
    [Abstract] [Full Text] [Related]

  • 2. Clinical value of F18-fluorodeoxyglucose positron emission tomography-computed tomography in patients with non-small cell lung cancer after potentially curative surgery: experience with 241 patients.
    Kanzaki R, Higashiyama M, Maeda J, Okami J, Hosoki T, Hasegawa Y, Takami M, Kodama K.
    Interact Cardiovasc Thorac Surg; 2010 Jun; 10(6):1009-14. PubMed ID: 20197344
    [Abstract] [Full Text] [Related]

  • 3. [Impact of positron emission tomography on clinical management of potentially resectable non-small-cell lung cancer: a French prospective multicenter study].
    Margery J, Milleron B, Vaylet F, Grahek D, Lebeau B, Mangiapan G, Bonardel G, de Labriolle-Vaylet C, Meignan M, Carette MF, Talbot JN, Housset B.
    Rev Pneumol Clin; 2010 Oct; 66(5):313-20. PubMed ID: 21087727
    [Abstract] [Full Text] [Related]

  • 4. Impact of 18F-FDG PET/CT in the treatment of patients with non-small cell lung cancer.
    Taus Á, Aguiló R, Curull V, Suárez-Piñera M, Rodríguez-Fuster A, Rodríguez de Dios N, Pijuan L, Zuccarino F, Vollmer I, Sánchez-Font A, Belda-Sanchis J, Arriola E.
    Arch Bronconeumol; 2014 Mar; 50(3):99-104. PubMed ID: 24360985
    [Abstract] [Full Text] [Related]

  • 5. Significance of a new fluorodeoxyglucose-positive lesion on restaging positron emission tomography/computed tomography after induction therapy for non-small-cell lung cancer.
    Collaud S, Lardinois D, Tischler V, Steinert HC, Stahel R, Weder W.
    Eur J Cardiothorac Surg; 2012 Mar; 41(3):612-6. PubMed ID: 22219415
    [Abstract] [Full Text] [Related]

  • 6. Mediastinal lymph nodes staging by 18F-FDG PET/CT for early stage non-small cell lung cancer: a multicenter study.
    Li X, Zhang H, Xing L, Ma H, Xie P, Zhang L, Xu X, Yue J, Sun X, Hu X, Chen M, Xu W, Chen L, Yu J.
    Radiother Oncol; 2012 Feb; 102(2):246-50. PubMed ID: 22100657
    [Abstract] [Full Text] [Related]

  • 7. First clinical results of (D)-18F-Fluoromethyltyrosine (BAY 86-9596) PET/CT in patients with non-small cell lung cancer and head and neck squamous cell carcinoma.
    Burger IA, Zitzmann-Kolbe S, Pruim J, Friebe M, Graham K, Stephens A, Dinkelborg L, Kowal K, Schibli R, Luurtsema G, Maas B, Horn-Tutic M, Haerle SK, Wiegers J, Schaefer NG, Hany TF, von Schulthess GK.
    J Nucl Med; 2014 Nov; 55(11):1778-85. PubMed ID: 25256060
    [Abstract] [Full Text] [Related]

  • 8. [Value of (18)F-FDG PET-CT in the preoperative N staging of non-small cell lung cancer].
    Li M, Wu N, Liang Y, Zheng R, Liu Y, Zhang WJ, Zhao P.
    Zhonghua Zhong Liu Za Zhi; 2009 Apr; 31(4):288-92. PubMed ID: 19615286
    [Abstract] [Full Text] [Related]

  • 9. Impact of whole-body ¹⁸F-fluorodeoxyglucose positron emission tomography on therapeutic management of non-small cell lung cancer.
    Heo EY, Yang SC, Yoo CG, Han SK, Shim YS, Kim YW.
    Respirology; 2010 Nov; 15(8):1174-8. PubMed ID: 20573060
    [Abstract] [Full Text] [Related]

  • 10. Diagnostic value of fluorine 18 fluorodeoxyglucose positron emission tomography/computed tomography for the detection of metastases in non-small-cell lung cancer patients.
    Wu Y, Li P, Zhang H, Shi Y, Wu H, Zhang J, Qian Y, Li C, Yang J.
    Int J Cancer; 2013 Jan 15; 132(2):E37-47. PubMed ID: 22890912
    [Abstract] [Full Text] [Related]

  • 11. Quantitative modifications of TNM staging, clinical staging and therapeutic intent by FDG-PET/CT in patients with non small cell lung cancer scheduled for radiotherapy--a retrospective study.
    Abramyuk A, Appold S, Zöphel K, Hietschold V, Baumann M, Abolmaali N.
    Lung Cancer; 2012 Nov 15; 78(2):148-52. PubMed ID: 22922126
    [Abstract] [Full Text] [Related]

  • 12. Thoracic staging with 18F-FDG PET/MR in non-small cell lung cancer - does it change therapeutic decisions in comparison to 18F-FDG PET/CT?
    Schaarschmidt BM, Grueneisen J, Metzenmacher M, Gomez B, Gauler T, Roesel C, Heusch P, Ruhlmann V, Umutlu L, Antoch G, Buchbender C.
    Eur Radiol; 2017 Feb 15; 27(2):681-688. PubMed ID: 27180186
    [Abstract] [Full Text] [Related]

  • 13. Thoracic staging in lung cancer: prospective comparison of 18F-FDG PET/MR imaging and 18F-FDG PET/CT.
    Heusch P, Buchbender C, Köhler J, Nensa F, Gauler T, Gomez B, Reis H, Stamatis G, Kühl H, Hartung V, Heusner TA.
    J Nucl Med; 2014 Mar 15; 55(3):373-8. PubMed ID: 24504054
    [Abstract] [Full Text] [Related]

  • 14. Improved detection of second primary cancer using integrated [18F] fluorodeoxyglucose positron emission tomography and computed tomography for initial tumor staging.
    Choi JY, Lee KS, Kwon OJ, Shim YM, Baek CH, Park K, Lee KH, Kim BT.
    J Clin Oncol; 2005 Oct 20; 23(30):7654-9. PubMed ID: 16234527
    [Abstract] [Full Text] [Related]

  • 15. Mediastinal staging in Non-Small-Cell Lung Carcinoma: computed tomography versus F-18-fluorodeoxyglucose positron-emission tomography and computed tomography.
    Harders SW, Madsen HH, Hjorthaug K, Arveschoug AK, Rasmussen TR, Meldgaard P, Hoejbjerg JA, Pilegaard HK, Hager H, Rehling M, Rasmussen F.
    Cancer Imaging; 2014 Jun 03; 14(1):23. PubMed ID: 25608616
    [Abstract] [Full Text] [Related]

  • 16. Diagnostic accuracy of virtual 18F-FDG PET/CT bronchoscopy for the detection of lymph node metastases in non-small cell lung cancer patients.
    Herbrik M, Treffert J, Geiger B, Riegger C, Hartung V, Rosenbaum-Krumme SJ, Forsting M, Antoch G, Heusner TA.
    J Nucl Med; 2011 Oct 03; 52(10):1520-5. PubMed ID: 21908390
    [Abstract] [Full Text] [Related]

  • 17. Clinical impact of (18)F fluorodeoxyglucose positron emission tomography in patients with non-small-cell lung cancer: a prospective study.
    Kalff V, Hicks RJ, MacManus MP, Binns DS, McKenzie AF, Ware RE, Hogg A, Ball DL.
    J Clin Oncol; 2001 Jan 01; 19(1):111-8. PubMed ID: 11134203
    [Abstract] [Full Text] [Related]

  • 18. False-negative rate after positron emission tomography/computer tomography scan for mediastinal staging in cI stage non-small-cell lung cancer.
    Gómez-Caro A, Boada M, Cabañas M, Sanchez M, Arguis P, Lomeña F, Ramirez J, Molins L.
    Eur J Cardiothorac Surg; 2012 Jul 01; 42(1):93-100; discussion 100. PubMed ID: 22290911
    [Abstract] [Full Text] [Related]

  • 19. Serial assessment of FDG-PET FDG uptake and functional volume during radiotherapy (RT) in patients with non-small cell lung cancer (NSCLC).
    Edet-Sanson A, Dubray B, Doyeux K, Back A, Hapdey S, Modzelewski R, Bohn P, Gardin I, Vera P.
    Radiother Oncol; 2012 Feb 01; 102(2):251-7. PubMed ID: 21885145
    [Abstract] [Full Text] [Related]

  • 20. Etiology of solitary extrapulmonary positron emission tomography and computed tomography findings in patients with lung cancer.
    Lardinois D, Weder W, Roudas M, von Schulthess GK, Tutic M, Moch H, Stahel RA, Steinert HC.
    J Clin Oncol; 2005 Oct 01; 23(28):6846-53. PubMed ID: 16192576
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.